Pathogenesis of psoriasis in the “omic” era. Part IV. Epidemiology, genetics, immunopathogenesis, clinical manifestation and treatment of psoriatic arthritis
Aneta Szczerkowska-Dobosz,Dorota Krasowska,Joanna Bartosińska,Marta Stawczyk-Macieja,Aleksandra Walczak,Agnieszka Owczarczyk-Saczonek,Adam Reich,Aleksandra Batycka-Baran,Rafał Czajkowski,Iwona T. Dobrucki,Lawrence W. Dobrucki,Magdalena Górecka-Sokołowska,Anna Janaszak-Jasiecka,Leszek Kalinowski,Roman J. Nowicki,Agata Płoska,Dorota Purzycka-Bohdan,Adrianna Radulska,Edyta Reszka,Dominik Samotij,Anna Siekierzycka,Andrzej T. Slominski,Radomir M. Slominski,Marta Sobalska-Kwapis,Dominik Strapagiel,Justyna Szczęch,Michał A. żmijewski,Bogusław Nedoszytko,Iwona Dobrucki,Lawrence Dobrucki,Roman Nowicki,Michał Żmijewski
DOI: https://doi.org/10.5114/ada.2020.100478
2020-01-01
Advances in Dermatology and Allergology
Abstract:Psoriatic arthritis (PsA) is a chronic, progressive, inflammatory arthropathy associated with psoriasis as well as a complex pathogenesis. Genetic and environmental factors trigger the development of the immune-mediated auto-inflammatory response in different sites: skin, bone marrow, entheses and synovial tissues. Studies of the last two decades have changed the view of PsA from a mild, non-progressive arthritis to an inflammatory systemic disease with serious health consequences, not only associated with joint dysfunction, but also with an increased risk of cardiovascular disease and socioeconomic consequences with significantly reduced quality of life. The joint damage starts early in the course of the disease, thus early recognition and treatment with modern biological treatments, which may modify the natural history and slow down progression of this debilitating disease, is essential for the patient long-term outcome.